Sugi Predict

Sugi Predict / Compounds / SCHEMBL28804348

SCHEMBL28804348

SCHEMBL28804348

CC(C)(C)OC(=O)N[C@@H]1C[C@H](O)CC12CCN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.45

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.45
▸ NAMPT P43490 14/20 0.42
▸ GPR119 Q8TDV5 2/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ USP2 O75604 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16925376 1.00 EPHX2 (0.45) EPHX2NAMPTGPR119EPHX1USP2
SCHEMBL18321912 0.90 BTK (0.37) EPHX2NAMPT
SCHEMBL22798665 0.90 BTK (0.37) EPHX2NAMPT
SCHEMBL26170760 0.84 BTK (0.42) EPHX1
SCHEMBL31184180 0.83 GPR119 (0.43) EPHX2NAMPTGPR119EPHX1USP2
SCHEMBL28542108 0.83 GPR119 (0.43) EPHX2NAMPTGPR119EPHX1USP2
SCHEMBL20337452 0.82 EPHX2 (0.41) EPHX2NAMPTGPR119EPHX1
SCHEMBL16925035 0.82 EPHX2 (0.41) EPHX2NAMPTGPR119EPHX1
SCHEMBL22084448 0.82 EPHX2 (0.41) EPHX2NAMPTGPR119EPHX1
SCHEMBL31184218 0.82 EPHX2 (0.41) EPHX2NAMPTGPR119EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753941-B1 PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) 2024-05-01 — — EP disclosed
US-20240101577-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. 2024-03-28 — — US disclosed
CN-115448923-B Pyrimidine-fused ring compound, preparation method and application thereof 上海青煜医药科技有限公司 2024-03-22 — — CN disclosed
CN-111433205-B Polycyclic compounds as allosteric SHP2 inhibitors 锐新医药公司 2024-01-19 — — CN disclosed
EP-3724189-B1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS REVOLUTION MEDICINES INC (US) 2023-10-04 — — EP disclosed
US-11673901-B2 Polycyclic compounds as allosteric SHP2 inhibitors Revolution Medicines, Inc. (US) 2023-06-13 — — US disclosed
US-11498930-B2 Pyrimidine-fused cyclic compound, preparation method therefor and application thereof Blueray Therapeutics (Shanghai) Co., Ltd (CN) 2022-11-15 — — US disclosed
CN-110156786-B Pyrimido-cyclic compounds, process for their preparation and their use 青煜医药研发(上海)有限公司 2022-06-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498930-B2 Pyrimidine-fused cyclic compound, preparation method therefor and application thereof PTPN11, PPM1F, PTPRF EPHX2 2404/4885NAMPT 388/4885GPR119 340/4885
US-11673901-B2 Polycyclic compounds as allosteric SHP2 inhibitors PTPN18, PTPN1, PTPRJ EPHX2 3091/4885NAMPT 1805/4885GPR119 616/4885
US-20240101577-A1 POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS PTPN18, PTPN1, PTPRJ EPHX2 3091/4885NAMPT 1805/4885GPR119 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.